

Joint Biological Agent Identification Diagnostic System (JBAIDS)

Protects personnel by rapidly identifying low levels of biological warfare agents and other pathogens encountered in field or hospital clinical laboratories.

INVESTMENT COMPONENT

Modernization

Recapitalization

Maintenance



Description & Specifications

The Joint Biological Agent Identification Diagnostic System (JBAIDS) can identify biological agents in a variety of environmental and clinical samples at or below 1,000 colony-forming units or 10,000 plaque-forming units per milliliter.

JBAIDS includes a clinical instrument based on commercial, off-the-shelf, non-developmental item technology requiring limited modification to meet operational requirements. Integrated with this instrument are reagent test kits for pathogen identification and protocols for sample preparation that,

when used together, can be cleared by the Food and Drug Administration as a diagnostic test.

- Detection Sensitivity: Equal to or better than 85 percent for identification of target agents at specified limit of detection concentrations
- Detection Specificity: Equal to or better than 90 percent for identification of target agents at specified limit of detection concentrations
- JBAIDS Block II upgrade will add the capability to identify toxins

Program Status

- 2QFY04: Critical design review
- 2QFY04: Developmental testing
- 4QFY04: Operational assessment; initial production decision
- 4QFY05: JBAIDS Block II competitive fly-off
- 2QFY06: Full rate production decision (Ground Systems)

Projected Activities

- 3QFY07: Follow-on test and evaluation
- 4QFY07: Full rate production decision (Naval Systems)

ACQUISITION PHASE

Concept & Technology Development

System Development & Demonstration

Production & Deployment

Operations & Support

**Joint Biological Agent
Identification Diagnostic System
(JBAIDS)**

FOREIGN MILITARY SALES

None

CONTRACTORS

Idaho Technologies (Salt Lake City, UT)

